CANDEL THERAPEUTICS Trademark
Trademark Overview
On Monday, January 28, 2019, a trademark application was filed for CANDEL THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the CANDEL THERAPEUTICS trademark a serial number of 88278673. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, June 2, 2020. This trademark is owned by Advantagene, Inc.. The CANDEL THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Conducting early evaluations in the field of new pharmaceuticals; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services in the field of cancer; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals fo...
General Information
| Serial Number | 88278673 |
| Word Mark | CANDEL THERAPEUTICS |
| Filing Date | Monday, January 28, 2019 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Tuesday, June 2, 2020 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Conducting early evaluations in the field of new pharmaceuticals; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services in the field of cancer; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific research for medical purposes in the area of cancerous diseases |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, February 20, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, November 1, 2018 |
| First Use In Commerce Date | Tuesday, January 1, 2019 |
Trademark Owner History
| Party Name | Advantagene, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Auburndale, MA 02466 |
Trademark Events
| Event Date | Event Description |
| Tuesday, June 2, 2020 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Tuesday, June 2, 2020 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Monday, October 21, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, October 21, 2019 | NON-FINAL ACTION E-MAILED |
| Monday, October 21, 2019 | NON-FINAL ACTION WRITTEN |
| Friday, October 4, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, October 4, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, October 4, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, April 10, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, April 10, 2019 | NON-FINAL ACTION E-MAILED |
| Wednesday, April 10, 2019 | NON-FINAL ACTION WRITTEN |
| Tuesday, April 9, 2019 | ASSIGNED TO EXAMINER |
| Wednesday, February 20, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, January 31, 2019 | NEW APPLICATION ENTERED IN TRAM |
